Envista Holdings Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Hi, everyone. Welcome to the 2021 JPMorgan Healthcare Conference. My name is Casey Woodring, and I'm a member of the Life Science Group and Diagnostics Equity Research team here at JPMorgan.
Today, it's my pleasure to introduce the management team of Envista. (Operator Instructions) And with that, let me turn it over to Amir.
Thank you, Casey. Thanks for having us. I'm going to refer to specific pages in here to get us started. I'll give you a little bit of a view of Envista on Page 3. We're about $2.8 billion based on 2019 revenue. This is all come off 28 acquisition as part of Danaher. We've been independent and publicly traded since September of 2019. About 55% gross margin, mid-teens EBITDA based on 2019.
It's commission of a large number of brands. Brands have been around for a long period of time and have tremendous amount of industry experience and knowledge. We're really like
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |